Download PDF
Nuklearmedizin 1995; 34(06): 232-242
DOI: 10.1055/s-0038-1629720
Original Article
Schattauer GmbH

Anti-CEA Labelling Kit BW 431/26

Results of the European Multicenter Trial
A. Steinsträßer
1   From the Radiochemical Laboratory of Hoechst AG. Frankfurt/Main and the Homburg/Saar, Germany
,
E. Oberhausen
2   Department of Nuclear Medicine of the Radiological University Clinics, Homburg/Saar, Germany
› Author Affiliations
Further Information

Publication History

Received: 10 March 1995

in revised form: 05 July 1995

Publication Date:
05 February 2018 (online)

    Permissions and Reprints

Summary

In seven European countries a multicenter trial with the 99mTc-labelled monoclonal anti-CEA antibody BW 431/26 was conducted in 730 patients. The antibody is used for the immunoscintigraphic visualisation of CEA-expressing tumours. Investigated were in particular colorectal tumours, bladder and breast carcinoma, medullary thyroid carcinoma, adenocarcinoma of the lung and gastric carcinoma. The main area of use is the detection of recurrences and screening for foci in patients with rising serum CEA. The sensitivity amounts to at least 80% in case of primary colorectal tumours (n = 129) and their abdominal or pelvic metastases (n = 33) and to 90% for their recurrences (n = 107). HAMAs were detectable in less than 15% of patients investigated for the first time. In 17% of the patients examined, immunoscintigraphy was the only technique to visualize the lesion whereas all other diagnostic methods had failed. The procedure yielded additional information in 24-51 % of cases.

Zusammenfassung

In sieben europäischen Ländern wurde mit dem 99mTc-markierten monoklonalen Anti-CEA-Antikörper BW 431/26 eine Multizenterstudie an 730 Patienten durchgeführt. Der Antikörper wird für die imimunoszintigraphische Darstellung von CEA-exprimierenden Tumoren eingesetzt. Insbesondere wurde neben kolorektalen Tumoren das Blasen- und Mamma-Ca sowie das medulläre Schilddrüsen-Ca, das Adeno-Ca der Lunge und das Magen-Ca untersucht. Das Hauptanwendungsgebiet liegt beim Rezidivnachweis und bei Patienten mit CEA-Anstieg im Serum. Die Sensitivität beträgt beim Nachweis des Primärtumors (n = 129) oder abdominaler bzw. pelviner Metastasen (n = 33) des kolorektalen Karzinoms mindestens 80% und beträgt 90% im Falle von Rezidiven (n = 107). HAMAs traten nach weniger als 15% der Erstuntersuchungen auf. Bei 17% der untersuchten Patienten konnte ausschließlich die Immunszintigraphie die Läsion darstellen, alle anderen diagnostischen Möglichkeiten hatten versagt. Zusätzliche Informationen konnten durch das Verfahren in 24-51 % der Fälle gewonnen werden.

Keywords

Immunoscintigraphy - monoclonal antibody BW 431/26 - 99mTc - carcinoembryonic antigen (CEA) - clinical multicenter trial

Schlüsselwörter

Immunszintigraphie - monoklonaler Antikörper BW 431/26 - 99mTc - karzinoembryo-nales Antigen (CEA) - klinische Multizenterstudie
 

  • REFERENCES

  • 1 Atkins HL, Hauser W, Richards P, Klopper J. Adverse reactions to radiopharmaceuticals. J Nucl Med 1972; 13: 232-3.
    PubMedGoogle Scholar
  • 2 Baew-Christow T, Baum RP, Hertel A, Lorentz M, Mondorf U, Hör G. Prospective clinical trial with Tc-99m-labelled monoclonal anti-CEA antibody in recurrent CEA-producing tumours. In: Recent results in tumour diagnosis and therapy. Klapdor R. (ed). München: Zuckschwerd; 1990: 388-92.
    Google Scholar
  • 3 Bares R. Tumor-Immunszintigraphie mit radioaktiv markierten monoklonalen Antikörpern. Der Nuklearmediziner 1992; 15: 261-72.
    Google Scholar
  • 4 Bares R, Fass J, Weiller G. et al. Planar vs SPECT radioimmunoscintigraphy (RIS): Clinical experience with Tc-99m, In-111, and 1-131 labelled monoclonal antibodies (MAB) against CEA and/or CA 19-9. Nucl-Med 1988; 24 Suppl 569-71.
    Google Scholar
  • 5 Barzen G, Felix R. Radioimmunszintigra-phie: Grundlagen (Teil 1). Acta Radiol 1992; 2: 255-61.
    Google Scholar
  • 6 Baum RP, Hertel A, Lorenz M. et al. Tc-99m labelled intact monoclonal anti-CEA Antibody for successful localization of tumour recurrences. Nucl-Med Suppl 1989; 25: 515-8.
    Google Scholar
  • 7 Baum RP, Hertel A, Lorenz M. et al. Tc-99m-labelled anti-CEA monoclonal antibody for tumour immunoscintigraphy: first clinical results. Nucl Med Commun 1989; 10: 345-52.
    CrossrefPubMedGoogle Scholar
  • 8 Baum RP, Lorenz M, Baew-Christow T. et al. Immunoscintigraphy of colorectal cancer. In: Immunoscintigraphy: Facts and fiction. Münz DL, Emrich D. (eds). Amsterdam: Elsevier; 1990: 95-104.
    Google Scholar
  • 9 Becker W, Wolf F. SPECT und andere Parameter zur Steigerung der diagnostischen Treffsicherheit bei der Immunszintigraphie. Der Nuklearmediziner 1991; 14: 137-44.
    Google Scholar
  • 10 Becker W, Bair HJ, Behr T, Wolf F. Indikationen zur Immunszintigraphie bei entzündlichen Erkrankungen und beim kolorektalen Karzinom. Der Nuklearmediziner 1994; 17: 251-72.
    Google Scholar
  • 11 Benz P, Dewes W, Hau U. et al. Radio-immunszintigraphie und Magnetresonanztomographie in der Diagnostik des Harnblasenkarzinoms. Nucl-Med 1992; 31: 74-9.
    Google Scholar
  • 12 Benz P, Oberhausen E, Berberich R. Monoclonal antibody BW 431/26 labelled with Technetium 99m and Indium 111: an investigation of the biodistribution and the dosimetry in patients. Eur J Nucl Med 1991; 18: 813-6.
    PubMedGoogle Scholar
  • 13 Bock E, Becker W, Scheele J, Wolf F. Diagnostic accuracy of 99mTc-anti-CEA immunoscintigraphy in patients with liver metastases from colorectal carcinoma. Nucl-Med 1992; 31: 80-3.
    Google Scholar
  • 14 Bosslet K, Lüben G, Schwarz A. et al. Immu-nohistochemical localization and molecular characteristics of three monoclonal antibody-defined epitopes detectable on carci-noembryonic antigen (CEA). Int J Cancer 1985; 36: 75-84.
    CrossrefPubMedGoogle Scholar
  • 15 Bosslet K, Steinsträßer A, Schwarz A. et al. Quantitative considerations supporting the irrelevance of circulating serum CEA for the immunoscintigraphic visualization of CEA expressing carcinomas. Eur J Nucl Med 1988; 14: 523-8.
    PubMedGoogle Scholar
  • 16 Büchler-Frederiksen P, Rasmussen JW. et al. 99mTc-anti-karcinoembryonalt antigen ved kolorektal cancer (99mTc-labelled anti-CEA monoclonal antibody in colorectal cancer). Ugeskr Laeger 1994; 156: 1641-5. Der Nuklearmediziner 1991; 14: 137-44.
    Google Scholar
  • 17 Cesnik H, Lechner P. Das Rezidiv des kolorektalen Karzinoms aus der Sicht des Chirurgen. Acta Med Austriaca 1989; 16: 17-21.
    Google Scholar
  • 18 Cristy M. Active bone marrow distribution as a function of age in humans. Phys Med Biol 1981; 26: 389-400.
    CrossrefPubMedGoogle Scholar
  • 19 Dippold WG, Wittig BM, Hach A, Hahn K, Meyer zum Büschenfeld KH. Immunoszinti-graphie bei kolorektalen Karzinomen aus der Sicht der Gastroenterologen. Z Gastroenterol 1990; 28: 673-7.
    PubMedGoogle Scholar
  • 20 Fräile M, Buxeda M, Castell J. et al. Anti-CEA monoclonal antibody 99mTc-BW 431/26 in the diagnostic workup of patients with colorectal cancer. Nucl Med Biol 1991; 18: 53-7.
    Google Scholar
  • 21 Fritzsche H. Immunoszintigraphische Kontrolluntersuchungen mit dem 99mTc-markierten monoklonalen Antikörper BW 431/26. Acta Med Austriaca 1990; 17: 44-6.
    PubMedGoogle Scholar
  • 22 Goldenberg DM, Larson SM. Radioimmun-detection in cancer identification. J Nucl Med 1992; 33: 803-14.
    PubMedGoogle Scholar
  • 23 Hach A, Wittig B, Piepenburg R. et al. Klinische Relevanz der Anti-CEA-Immunszinti-graphie mit dem 99mTc-markierten monoklonalen Antikörper BW 431/26. Fortschr Röntgenstr 1992; 157: 3-10.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Hach A, Wittig B, Schmitz A, Bockisch A, Hahn K. 99mTc-Scintimun (BW 431/26) versus ‘“In-Oncoscint CR 103: Simultane Applikation bei Patienten mit kolorektalen Karzinomen. Nucl-Med 1993; 32: A33.
    Google Scholar
  • 25 Hertel A, Baum RP, Lorenz M. et al. Immunoscintigraphy using a technetium-99m labelled monoclonal anti-CEA antibody in the follow-up of colorectal cancer and other tumors producing CEA. Br J Cancer 1990; 62: 34-6.
    Google Scholar
  • 26 Hertel A, Baum RP, Auerbach B, Herrmann A, Hör G. Klinische Relevanz humaner Anti-Maus-Antikörper (HAMA) in der Immunszintigraphie. Nucl-Med 1990; 29: 221-7.
    Google Scholar
  • 27 ICRP Publication 26. Recommendations of the ICRP. Annals of the ICRP 1. Oxford: Pergamon Press; 1977
    Google Scholar
  • 28 ICRP Publication 60. 1990 Recommendations of the ICRP. Annals of the ICRP 21. Oxford: Pergamon Press; 1991
    Google Scholar
  • 29 Johansson L, Mattsson S, Nosslin B. Effective dose equivalent from radiopharmaceuticals. Eur J Nucl Med 1984; 9: 485-9.
    CrossrefPubMedGoogle Scholar
  • 30 Kairemo KJA, Tiusanen KJ. Immunolym-phoscintigraphy with Tc-99m-labelled monoclonal anti-CEA antibodies in breast cancer. Nucl-Med 1989; 25 Suppl 683-5.
    Google Scholar
  • 31 Kalevi J, Kairemo A. Immunolymphoscin-tigraphy with 99m-Tc-labelled monoclonal antibody (BW 431/26) reacting with carci-noembryonic antigen in breast cancer. Cancer Research (Suppl) 1990; 50: 949-54.
    Google Scholar
  • 32 Kanokogi M, Becht E, Benz P. et al. Karzino-embryonales Antigen (CEA) beim Harnblasenkarzinom: Eine immunhistochemische und immunoszintigraphische Untersuchung. Acta Urol 1990; 21: 251-8.
    Google Scholar
  • 33 Keeling DH. Clinical emergencies in the nuclear medicine department. Nucl Med Commun 1988; 9: 259-61.
    CrossrefPubMedGoogle Scholar
  • 34 von Kleist S. Das karzinoembryonale Antigen (CEA). Stuttgart - New York: Schattauer; 1983
    Google Scholar
  • 35 König B, Röhle R, Köhn H, Mostbeck A. Ergebnisse der quantitativen Messung des CEA-Antikörper-Uptake (BW 431/26) im Tumor. Acta Med Austriaca 1989; 16: 25-8.
    Google Scholar
  • 36 Kramer W, Baum RP, Hör G, Jonas D. Immunszintigraphie bei entzündlichen und malignen Erkrankungen: Antileukozyten- und Antitumorantikörper. Urologe [A] 1993; 32: 108-14.
    Google Scholar
  • 37 Kroiss A, Tuchmann A, Schüller J. et al. Im-munszintigraphische Tumordiagnostik mit Anti-CEA-Antikörpern (Tc-99m MAK BW 431/26). Wien Klin Wschr 1989; 101: 621-6.
    PubMedGoogle Scholar
  • 38 Leitha T, Walter R, Schlick W, Dudczak R. 99mTc-Anti-CEA radioimmunoscintigraphy of lung adenocarcinoma. Chest 1991; 99: 14-9.
    PubMedGoogle Scholar
  • 39 Leitha T, Baur M, Steger D, Dudczak R. Anti-CEA-Immunoszintigraphie in der postoperativen Nachsorge von Tumorpatienten. Wien Klin Wschr 1990; 102: 503-9.
    PubMedGoogle Scholar
  • 40 Lind P, Langsteger W, Költringer P, Arian-Schad K, Eber O. 99mTc-labelled monoclonal anti-carcinoembryonic antigen antibody (BW 431/26). Clinical results in the detection of colorectal carcinomas and recurrences. Scand J Gastroenterol 1989; 24: 1205-11.
    CrossrefPubMedGoogle Scholar
  • 41 Lind P. Immunoscintigraphy of colorectal carcinomas and recurrences with a techne-tium-99m-labelled monoclonal anti-CEA-antibody (MAB BW 431/26). J Nucl Med 1990; 31: 535-6.
    PubMedGoogle Scholar
  • 42 Lind P, Lechner P, Kuttnig M. et al. Differentiation of lymph-node metastases by anti-CEA immunoscintigraphy in a patient with follicular thyroid and breast cancer. Nucl-Med 1990; 29: 278-81.
    Google Scholar
  • 43 Lind P, Lechner P, Arian-Schad K. et al. Anti-carcinoembryonic antigen immunoscintigraphy (technetium-99m-monoclonal antibody BW 431/26) and serum CEA levels in patients with suspected primary and recurrent colorectal carcinoma. J Nucl Med 1991; 32: 1319-25.
    PubMedGoogle Scholar
  • 44 Lind P, Langsteger W, Költringer P. et al. Diagnostik kolorektaler Karzinome und Rezidive mit einem 99m-Tc-markierten monoklonalen Anti-CEA-Antikörper (BW 431/26). Acta Med Austriaca 1989; 16: 22-4.
    Google Scholar
  • 45 Mostbeck A. Die Probability Map als Entscheidungshilfe in der Immunszintigraphie. Acta Med Austriaca 1989; 16: 29-32.
    Google Scholar
  • 46 Muxi A, Sola M, Bassa P. et al. Radioimmunoscintigraphy of colorectal carcinoma with a 99m-Tc-labelled anti-CEA monoclonal antibody. Nucl Med Commun 1992; 13: 261-70.
    CrossrefPubMedGoogle Scholar
  • 47 Neumann K, Cordes M, Dorow M. et al. Nuklearmedizinische Diagnostik beim Bronchialkarzinom. Med Klin 1991; 86: 309-17.
    Google Scholar
  • 48 Oberhausen E, Steinsträßer A, Schroth HJ, Klein A, Berberich R. Immunoscintigraphy of colorectal tumors with the monoclonal antibody BW 431/26. In: Radioakt. Isotope in Klinik und Forschung 17. Höfer R, Bergmann H. (eds). Wien: Egermann; 1986: 397-402.
    Google Scholar
  • 49 Oberhausen E, Klein A, Berberich R. Clinical trial of MAB 431/31 and MAB 431/26 labelled with different radionuclides. Nucl-Med 1988; 24 Suppl 620-4.
    Google Scholar
  • 50 Perkins AC, Pimm MV, Durant LG. HAMA - a serious problem for immunoscintigraphy?. Eur J Nucl Med 1988; 14: C8.
    Google Scholar
  • 51 Pimm MV, Perkins AC, Gribben SJ, Mark-ham AJ. Mouse-specific antibody response to a monoclonal antibody during repeated immunoscintigraphy in investigations: comparison of antibody titres and imaging studies in a rat model. Eur J Nucl Med 1990; 17: 216-22.
    CrossrefPubMedGoogle Scholar
  • 52 Radiopharmaceuticals. Commission of the European Communities, Note for Guidance 111/3936/89.
  • 53 Radiopharmaceuticals based on monoclonal antibodies. Commission of the European Communities, Note for Guidance 111/3487/89.
    Google Scholar
  • 54 Reiners C. Die Strahlenexposition in der nuklearmedizinischen Diagnostik: Risikovergleich auf der Basis effektiver Dosen. Nucl-Med 1993; 32: 47-51.
    Google Scholar
  • 55 Reske SN, Büll U. Reduced technetium 99m labelled NCA-95/CEA-antibody uptake in liver due to gentle antibody reconstruction. Eur J Nucl Med 1990; 17: 38-41.
    CrossrefPubMedGoogle Scholar
  • 56 Rettenbacher G, Galvan G. Anaphylakti-scher Schock nach wiederholter Injektion von 99mTc-markiertem CEA-Antikörper. Nucl-Med 1994; 33: 127-8.
    Google Scholar
  • 57 Reuland P, Kaiser W, Elmer D, Teichmann B. Increase of the CEA-blood-level: indication for immunoscintigraphy?. Eur J Nucl Med 1990; 16: 410.
    Google Scholar
  • 58 Reuter M, Montz R, de Heer K. et al. Detection of colorectal carcinomas by intraoperative RIS in addition to preoperative RIS: surgical and immunohistochemical findings. Eur J Nucl Med 1992; 19: 102-9.
    CrossrefPubMedGoogle Scholar
  • 59 Rilinger N, Münz DL, Niemann H, Illinger HJ, Halbfaß HJ. Immunoscintigraphy using different methods of applying a Tc-99m labelled monoclonal anti-CEA-antibody in the staging of patients with liver metastases before partial hepatectomy. Int J Nucl Med Biol 1991; 18: 65-8.
    Google Scholar
  • 60 Roedler HD, Lechel U, Moser EA. Strahlenexposition des Patienten bei der Radioim-munszintigraphie. Der Nuklearmediziner 1987; 10: 289-92.
    Google Scholar
  • 61 Sandrock D, Blossey HC, Steinroeder M. Contribution of different scintigraphic techniques to the management of medullary thyroid carcinoma. Henry Ford Hosp Med J 1989; 37: 173-4.
    PubMedGoogle Scholar
  • 62 Steinsträßer A, Schwarz A, Kuhlmann L. et al. Preclinical and clinical testing of radiolabeled monoclonal antibodies for immunoscintigraphy. Develop Biol Standard 1990; 71: 137-45.
    Google Scholar
  • 63 Steinsträßer A, Berberich R, Schwarz A. et al. Radiation dose due to scintigraphy using the granulocyte selective monoclonal antibody BW 250/183. Nucl-Med 1991; 27: 142-4.
    Google Scholar
  • 64 Williams LE, Bares RB, FAss J. et al. Uptake of radiolabeled anti-CEA antibodies in human colorectal primary tumours as a function of tumour mass. Eur J Nucl Med 1993; 20: 345-7.
    PubMedGoogle Scholar